Cargo Therapeutics, Inc. CRGX
We take great care to ensure that the data presented and summarized in this overview for CARGO Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in CRGX
Top Purchases
Top Sells
About CRGX
Insider Transactions at CRGX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 14
2025
|
Shishir Gadam Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+40.14%
|
-
|
|
Mar 14
2025
|
Gina Chapman President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+39.69%
|
-
|
|
Mar 14
2025
|
Ginna Laport Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+50.0%
|
-
|
|
Mar 14
2025
|
Anup Radhakrishnan |
BUY
Grant, award, or other acquisition
|
Direct |
72,500
+47.87%
|
-
|
|
Sep 19
2024
|
Gina Chapman President & CEO |
SELL
Open market or private sale
|
Direct |
2,975
-2.78%
|
$74,375
$25.03 P/Share
|
|
Sep 19
2024
|
Gina Chapman President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,975
+2.71%
|
$14,875
$5.03 P/Share
|
|
Sep 18
2024
|
Gina Chapman President & CEO |
SELL
Open market or private sale
|
Direct |
7,166
-6.45%
|
$179,150
$25.09 P/Share
|
|
Sep 18
2024
|
Gina Chapman President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,166
+6.06%
|
$35,830
$5.03 P/Share
|
|
Sep 18
2024
|
Anup Radhakrishnan |
SELL
Open market or private sale
|
Direct |
1,600
-19.89%
|
$40,000
$25.28 P/Share
|
|
Sep 18
2024
|
Anup Radhakrishnan |
BUY
Exercise of conversion of derivative security
|
Direct |
1,600
+16.59%
|
$8,000
$5.03 P/Share
|
|
May 30
2024
|
Samsara Bio Capital Gp, LLC |
BUY
Open market or private purchase
|
Indirect |
294,000
+6.24%
|
$4,998,000
$17.0 P/Share
|
|
Jan 12
2024
|
Rtw Investments, LP > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
1,842,499
-26.25%
|
-
|
|
Nov 14
2023
|
Samsara Bio Capital Gp, LLC |
BUY
Open market or private purchase
|
Indirect |
666,666
+13.92%
|
$9,999,990
$15.0 P/Share
|
|
Nov 14
2023
|
Samsara Bio Capital Gp, LLC |
BUY
Conversion of derivative security
|
Indirect |
3,381,323
+49.46%
|
-
|
|
Nov 14
2023
|
Wellington Biomedical Innovation Master Investors (Cayman) Ii L.P. |
BUY
Conversion of derivative security
|
Direct |
737,000
+50.0%
|
-
|
|
Nov 14
2023
|
Third Rock Ventures V, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,333,333
+42.46%
|
$19,999,995
$15.0 P/Share
|
|
Nov 14
2023
|
Third Rock Ventures V, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
473,786
+50.0%
|
-
|
|
Nov 14
2023
|
Third Rock Ventures V, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
1,737,216
+50.0%
|
-
|
|
Nov 14
2023
|
Perceptive Advisors LLC |
BUY
Open market or private purchase
|
Indirect |
666,666
+30.13%
|
$9,999,990
$15.0 P/Share
|
|
Nov 14
2023
|
Perceptive Advisors LLC |
BUY
Conversion of derivative security
|
Indirect |
2,579,502
+50.0%
|
-
|
Last 12 Months Summary
Buy / Acquisition
688K
Shares
From
7
Insiders
| Grant, award, or other acquisition | 383K shares |
|---|---|
| Exercise of conversion of derivative security | 11.7K shares |
| Open market or private purchase | 294K shares |
Sell / Disposition
11.7K
Shares
From
2
Insiders
| Open market or private sale | 11.7K shares |
|---|